ilaprazole + amoxicillin

Ilaprazole + amoxicillin is a dual-drug combination used primarily for the eradication of *Helicobacter pylori* infection. Ilaprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the Hydrogen/potassium ATPase enzyme in gastric parietal cells, thereby increasing gastric pH and enhancing the effectiveness of antibiotics against *H. pylori*[6][1]. Amoxicillin is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis, leading to bacterial cell death[4]. This combination has been studied as an alternative to standard triple or quadruple therapies for *H. pylori* eradication, with clinical trials showing variable efficacy depending on dosing regimens and patient populations[1][2][3][5]. Ilaprazole was developed by Il-Yang Pharmaceutical (Korea) and is marketed in several countries for acid-related disorders; amoxicillin is widely manufactured globally.